JD Health Reports Full-Year 2022 Results: RMB 46.7 Billion in Revenue, Advancing Inclusive Healthcare and Social Impact

On March 22, 2023, JD Health International Inc. (stock abbreviation: “JD Health”, 6618.HK) released its annual results announcement for 2022. During the reporting period, JD Health’s total revenue was RMBRMB 46.7 billion, year-on-year growth52.3%, net profit under Non-IFRS measures reached2.62 billion yuan, year-on-year growth86.6%; as of December 31, 2022, the number of annual active users in the past 12 months exceeded154 million, compared to the net increase in annual active users as of December 31, 202131 million. The number of pharmaceutical and non-pharmaceutical warehouses nationwide increased to22 itemsand over500 units, the "self-operated cold chain" capability for pharmaceuticals has covered more than300 unitsCities, JD Health Internet Hospital's average daily online consultation volume exceeds300,000, JD Pharmacy served over 100 million patients in one year.

JD Health CEO Jin Enlin“Over the past year, JD Health has consistently aligned with national policies and regulatory guidelines. Guided by our business philosophy of ‘creating trustworthy, user-health-centric value,’ we have continuously opened up the ecosystem capabilities of our ‘retail pharmacy + healthcare services’ model to effectively address the public’s needs and urgent concerns. Throughout this process, we have remained focused on users’ health needs, aiming for quality growth by building an integrated online-offline healthcare service ecosystem. This supports the realization of ‘inclusive healthcare’ and demonstrates our commitment to creating long-term, sustainable value for shareholders and society as a whole.”

“Pandemic Response and Supply Assurance” is a concentrated reflection of the social and user value created by JD Health. Particularly during the year-end and early-year period, under the guidance of China’s Ministry of Industry and Information Technology, JD Health customized and launched the “COVID-19 Patient Medication Assurance Platform” for 21 provincial-level administrative regions across China, effectively ensuring stable supplies of scarce epidemic prevention materials. Additionally, JD Health collaborated with over 100 regional governments to launch official online medical service platforms, serving residents in various localities. Actively responding to the call to support grassroots epidemic prevention, JD Health jointly initiated the “Rural Epidemic Prevention Guardian Action” with the National Rural Revitalization Administration and People’s Daily New Media, meeting villagers’ demands for anti-pandemic medications. Meanwhile, JD Health also launched the “Epidemic Protection and Home Treatment Consultation Platform” and the “Pandemic Mutual Aid Platform” to serve and assist a broader population. Furthermore, JD Health continuously advanced the implementation of multiple public welfare projects, donating cash, medical health supplies, and services totaling over RMB 10 million throughout the year. It orderly carried out the JD Health Rare Disease Care Program, organizing 34 rare disease public welfare activities and launching the “Rare Disease Medical Consultation Map,” dedicated to helping nearly 20 million rare disease patients in China effectively reduce their costs of seeking medical care and medication.

Overall, in 2022, JD Health consistently adhered to its strategic positioning as a health management enterprise that leverages the pharmaceutical and health product supply chain as its core, medical services as its key driver, and digital technology to provide full-lifecycle, all-scenario health management for users. Whether in areas of social value—such as combating the COVID-19 pandemic, supporting rural revitalization, providing patient assistance, and caring for the health of key populations—or in areas of industry value—such as collaborating with partners to promote the digital and intelligent transformation and upgrading of the industry—JD Health has continued to build new capabilities, offer new services, and explore new partnerships. It has constantly expanded the breadth and depth of “inclusive healthcare,” making accessible, convenient, and affordable inclusive healthcare available to more people.

In its retail pharmacy business, JD Health has further diversified its operational models to deliver a superior integrated online-to-offline user experience, thereby strengthening user trust. During the reporting period, JD Pharmacy served over 100 million users in one year, fully leveraging the social value of its pharmaceutical and healthcare supply chain to improve the accessibility of medical and health services.

During the reporting period, JD Health continuously strengthened its pharmaceutical and healthcare product supply chain network covering all scenarios. As of December 31, 2022, JD Health utilized 22 pharmaceutical warehouses and over 500 non-pharmaceutical warehouses nationwide through JD Logistics. The “self-operated cold chain” capability of JD Pharmacy has covered more than 300 cities across China, and JD Pharmacy’s DTP (Direct to Patient) pharmacies, which provide professional services directly to patients, carried over 400 specialty drug varieties. JD Health also opened its first hearing center in Beijing, offering users a one-stop service for professional and convenient hearing aid fitting and purchase.

In 2022, JD Health entered into strategic collaborations with globally leading pharmaceutical companies and health product suppliers, becoming one of the most important partners for global pharmaceutical and healthcare brands to expand omnichannel business and achieve digital marketing in China. During the reporting period, JD Health was committed to comprehensively enhancing the accessibility of new and specialty drugs, and further improving its industry-leading online retail network and safe medication system for such drugs. During the reporting period, JD Health also deepened its cooperation with numerous nutritional and healthcare brands, leveraging its digital and intelligent C2M (Consumer-to-Manufacturer) reverse customization capabilities to further enhance supply chain efficiency.

As of December 31, 2022, JD Health’s online platform hosted over 20,000 third-party merchants. By providing a more comprehensive operational support system and digital marketing strategies, the company helped these merchants achieve growth. During the reporting period, the omnichannel service “JD Medicine Express” focused on building its “rapid consultation + fast medication delivery” capabilities and began operating the pharmaceutical and health product categories on “JD Daojia.” As of December 31, 2022, “JD Medicine Express” partnered with over 70,000 merchants to provide round-the-clock services, earning greater trust from users.

In 2022, JD Health remained user-centric, continuously building an integrated online-offline new healthcare service system. By offering a range of services including specialized medical care, consumer healthcare, and health management, JD Health achieved comprehensive user health management across all scenarios and throughout the entire lifecycle, while accelerating the universal accessibility of high-quality healthcare services across society. During the period of normalized pandemic prevention and control, JD Health not only facilitated timely and convenient medical access for the public but also effectively alleviated the diagnostic and treatment pressures on offline medical institutions.

During the reporting period, JD Health focused on user experience by optimizing service processes and product interactions, thereby enriching its portfolio of medical and healthcare service offerings. As of December 31, 2022, JD Health’s Internet Hospital had established more than 150 secondary clinical departments, with an average daily volume of online consultations exceeding 300,000 throughout the year. Notably, following the optimization of pandemic prevention and control measures, JD Health promptly launched fever clinic services, reaching a peak single-day consultation volume of over 1.14 million during high-demand periods. During the reporting period, JD Health also developed comprehensive post-diagnosis service solutions tailored for hospitals, departments, and physicians, leveraging digital and intelligent tools to significantly enhance the work efficiency of healthcare professionals.

JD Health’s “managed care” product, JD Family Doctor, has expanded its services to cover multiple scenarios, including online consultations, offline medical visits, and health management. JD Health’s consumer healthcare business continues to enhance the integrated online-to-offline (O2O) medical and health service experience through in-store and at-home service models. It also integrates with specialized medical services, offering solutions such as appointment scheduling for physical examinations and online interpretation of examination reports, vaccine appointments and vaccination consultations, early screening for critical illnesses, and follow-up medical guidance. As of December 31, 2022, more than 1,300 service providers had joined the platform, with 40,000 stores covering over 500 cities and regions across China.

In 2022, JD Health actively promoted the implementation of innovative businesses and accelerated the digital upgrade of healthcare services across all scenarios through technological upgrades and open, customized, and digital-intelligent solutions, fully leveraging the social value of digital healthcare services in safeguarding public health and improving the accessibility of medical services.

Over the past year, JD Health has continuously expanded its health service solutions for corporate clients, launching offerings such as smart physical examinations and corporate Employee Assistance Programs (EAP), thereby gaining greater favor among enterprise customers. As of the end of 2022, the number of partnered corporate clients had exceeded 4,600.

During the reporting period, JD Health innovatively developed a “Digital-Intelligent Healthcare” solution system. By leveraging its “Technology Open Platform,” “Big Data Application System,” “Operations Support System,” and “Supply Chain Management System,” the company optimized patient care pathways and improved consultation efficiency, thereby promoting the deep integration of next-generation information technologies with medical services. During the reporting period, JD Health collaborated with more than 20 hospitals to jointly establish internet hospitals.

In 2022, JD Health acquired the pet health category assets from JD.com, establishing an online closed-loop ecosystem for pet “medical care + pharmaceuticals.” Building on this foundation, it launched the new “JD Pet Health” brand to create a one-stop pet care service platform covering all scenarios and the entire lifecycle of pets.

JD Health actively fulfills its corporate social responsibility, leveraging its corporate social value in multiple areas, including the fight against the COVID-19 pandemic, support for rural revitalization, and patient assistance programs.

During the pandemic, JD Health joined forces with numerous pharmaceutical and medical device partner brands to ensure stable supply and pricing. It successively donated masks, antigen tests, and medicines to various regions across China and provided medical service assistance. JD Health Internet Hospital urgently launched an online “Fever Clinic” service, enhancing patient access to care and effectively alleviating pressure on offline medical institutions. Additionally, JD Health actively cooperated with the Ministry of Industry and Information Technology to guarantee a stable supply of scarce medicines and materials in remote areas.

In 2022, JD Health continued to advance the implementation of multiple public welfare initiatives, donating cash, medical and health supplies, and services with a total value exceeding RMB 10 million throughout the year. Nearly 50,000 third-party merchants on JD.com participated in the “Love Dongdong” campaign, contributing over 46.21 million donations to medical and health-related public welfare projects during the year. By collaborating with various partners, JD Health facilitated the ongoing implementation of public welfare programs such as the JD Health Rare Disease Care Initiative and the JD Health Special Medical Food Action.

JD Health collaborates with various industry stakeholders to advance standardized development in the healthcare sector: by partnering with authoritative institutions, it promotes the establishment of standard systems for multiple tonic categories, including goji berries, bird’s nest, and cordyceps, thereby fostering standardized growth in the tonic industry; it releases expert consensus on internet-based diagnosis and treatment for psychiatric specialties, endocrinology specialties, and out-of-hospital hypertension management, along with 201 standardized clinical pathways, to enhance quality control and service standards in internet healthcare; furthermore, it strengthens its own information security infrastructure, becoming the first enterprise in the internet healthcare industry to achieve BSI ISO 27799 certification for Personal Health Information Security Management Systems.

Looking ahead, JD Health will continue to uphold its business philosophy of “creating trustworthy, user health-centric value.” On one hand, it will focus on building an integrated online-to-offline new healthcare service system, leveraging digital and intelligent technologies to deliver accessible, convenient, and affordable inclusive healthcare to a broader population. On the other hand, JD Health will continue to open up its pharmaceutical and healthcare supply chain, as well as its medical and healthcare service capabilities and resources. By focusing on users’ health needs and collaborating with partners across society, JD Health is committed to integrating and advancing corporate social value alongside industry value, ultimately accelerating the implementation of the “Healthy China 2030” initiative.

Note: The financial data in this article are excerpted from the company’s performance announcement. Please refer to the full version of the performance announcement for the final and authoritative information.